Company Announcements

Results of Annual General Meeting

Source: RNS
RNS Number : 1871O
Advanced Medical Solutions Grp PLC
08 June 2022
 

8 June 2022

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Results of Annual General Meeting

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that at the Company's Annual General Meeting held today at 11 am at the Offices of Investec Bank plc, 30 Gresham Street, London, EC2V 7QP, all resolutions were duly passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 29 April 2022.

 

The poll results were as follows.

 

Resolution

 

Title

For (see note 2)

Against (see note 2)

No. of shares

%

No. of shares

%

1

Receive Annual Report and Accounts

122,189,273

99.99

2,000

0.01

2

Approve the Remuneration Report

121,168,966

99.02

1,198,956

0.98

3

Re-appoint Deloitte LLP as auditors

116,797,783

95.92

4,969,411

4.08

4

Re-elect Peter Allen

103,388,287

89.10

12,651,027

10.90

5

Re-elect Grahame Cook

113,183,101

92.49

9,190,030

7.51

6

Elect Douglas Le Fort

115,464,984

99.27

844,330

0.73

7

Re-elect Chris Meredith

120,304,522

98.31

2,068,609

1.69

8

Re-elect Eddie Johnson

122,028,446

99.72

344,685

0.28

9

Declare final dividend

122,378,935

99.99

1,121

0.01

10

Authorise allotment of shares

117,948,199

96.38

4,430,807

3.62

11

Disapply pre-emption rights*

108,025,798

88.28

14,345,022

11.72

12

Authorise purchase of own shares*

94,316,659

99.05

907,369

0.95

*  Special Resolution

Notes:

1.  Votes "For" and "Against" are expressed as a percentage of votes received.

2.  A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

3.  Total number of shares in issue at close of business on 6 June = 216,626,583 shares. 56% of the voting capital was instructed.

 

- Ends -

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer



 

Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Matthew Cole

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Daniel Adams / Gary Clarence




HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish


 

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made four acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies, Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products and AFS Medical, a specialist distributor of minimally invasive surgical devices based in Austria.

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFLFSFRDITIIF